Medical Device Global Market Access

Pure Global

Navigate every market. Accelerate every launch. Medical Device Global Market Access by Pure Global is the audio briefing that turns the world’s most confusing regulatory pathways into clear, actionable roadmaps. If you’re a MedTech founder, RA/QA leader, product manager, or investor who needs to get devices cleared anywhere from Austin to Abu Dhabi, this show is your shortcut. Why listen? • Step-by-step playbooks – We decode EU MDR, U.S. 510(k), Brazil’s ANVISA, China’s NMPA, and 25 + other regimes, showing exactly how long each milestone really takes and where companies get stuck. • First-hand war stories – Hear candid interviews with regulatory veterans who have shepherded implants, software, wearables, diagnostics, and AI algorithms to market—and lived to tell the tale. • Real-time intelligence – Every episode covering the week’s new guidances, standards, and enforcement trends so you’re always ahead of the curve. • Actionable templates – From clinical evaluation checklists to technical-file skeletons, we break down the documents you’ll need and the pitfalls reviewers love to flag. • AI-powered insights – Because Pure Global mines millions of public filings, tenders, and recalls, we surface data-backed best practices you won’t hear at conferences—or from competitors. What you’ll hear • Launching SaMD under multiple risk classes in parallel • Surviving an unannounced ISO 13485 audit • Building a “reg-first” QMS that scales • Mastering Latin-American registrations without endless language cycles • Leveraging real-world evidence to shorten clinical timelines • Aligning cybersecurity, privacy, and post-market surveillance rules across regions Whether you’re plotting first entry, managing lifecycle expansions, or rescuing a delayed submission, subscribing could shave months—and millions—off your path to revenue. ⸻ Brought to you by Pure Global – the AI-native consultancy that already guides MedTech innovators through regulatory and market-access hurdles in 30 + countries. Ready for expert help on your next submission? Visit https://pureglobal.com or email info@pureglobal.com to start accelerating today.

  1. 18時間前

    South Korea Medical Device Act 2026: MFDS QMS and Distribution Rule Changes

    This episode details the significant amendments to South Korea's Medical Device Act, effective July 1, 2026. We cover the two key changes from the Ministry of Food and Drug Safety (MFDS): the formalization of the Quality Management System (QMS) Conformity Recognition Scheme and the new mandatory supply chain record-keeping rules. We explore the impact on manufacturers, importers, and distributors and provide actionable steps for regulatory and quality teams to ensure compliance with these new traceability and oversight requirements. Key Questions: - What are the key changes in South Korea's amended Medical Device Act effective July 1, 2026? - How does the formalization of the QMS Conformity Recognition Scheme impact MFDS audits? - What new traceability and record-keeping requirements are being imposed on the medical device supply chain? - Who is responsible for maintaining distribution records under the new MFDS rules? - How does this amendment affect manufacturers, importers, distributors, and sellers in South Korea? - Can participation in programs like MDSAP simplify compliance with the new QMS requirements? - What practical steps should my regulatory team take now to prepare for the 2026 deadline? - How will these changes enhance patient safety and post-market surveillance in South Korea? Sources: - https://www.regdesk.co/south-korea-mfds-2026-medical-device-act-amendments-qms-conformity-recognition/ - https://www.youtube.com/watch?v=YOUR_VIDEO_ID_FOR_RESULT_16 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, simplifying global market access. We act as your local representative in over 30 markets, including South Korea, and develop efficient regulatory strategies to get your products approved faster. Our AI-powered platform streamlines the creation and management of technical dossiers for MFDS submissions. We help you navigate complex requirements like the new distribution rules and ensure your QMS aligns with local expectations. Visit https://pureglobal.com or contact us at info@pureglobal.com. Explore our free AI tools and device database at https://pureglobal.ai.

  2. 1日前

    Saudi Arabia SFDA Risk Communication Guidance: What MDS-G-029 Means for Manufacturers

    The Saudi Food and Drug Authority (SFDA) published a new guidance, MDS-G-029, on July 9, 2026, establishing formal requirements for medical device risk communication. This episode breaks down the key principles of the guidance, including the responsibilities of manufacturers and their Authorized Representatives, the expected content and channels for communication, and the impact on post-market surveillance and vigilance systems for devices sold in Saudi Arabia. Key Questions: - What is the new SFDA guidance MDS-G-029 about? - Who does this new risk communication requirement apply to? - What are the key principles for communicating medical device risks in Saudi Arabia? - What specific information must be included in a risk communication notice? - How does this guidance impact manufacturers' post-market surveillance obligations? - What is the role of the Authorized Representative in this process? - What are the different types of communication channels the SFDA expects? - What practical steps should my team take now to prepare for compliance? Sources: - https://www.sfda.gov.sa/sites/default/files/2026-07/MDS-G-029-V1.pdf - https://www.sfda.gov.sa/en/medicaldevices How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including Saudi Arabia, and our experts can help you align your post-market surveillance and vigilance systems with new requirements like the SFDA's MDS-G-029. Our AI-powered tools accelerate the creation of technical documentation and help you monitor regulatory changes, ensuring continuous compliance. Whether you need to develop a regulatory strategy, manage submissions, or maintain your market presence, we offer a single, efficient process for multiple markets. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more and access our free regulatory AI tools and database at https://pureglobal.ai.

  3. 2日前

    Health Canada Ministerial Reliance Order: Faster Market Access for Medical Devices

    Health Canada has introduced a new Ministerial Reliance Order, effective July 15, 2026, designed to accelerate market access for medical devices and drugs. This episode breaks down how the new reliance pathway allows manufacturers to leverage approvals from trusted foreign regulators to expedite the Canadian review process. We discuss the potential eligibility criteria, the critical public consultation period ending on September 12, 2026, and provide practical, actionable steps for regulatory and quality teams to prepare their submission strategies. Key Questions: - What is Health Canada's new Ministerial Reliance Order? - How does this order accelerate the review process for medical devices? - Which foreign regulatory approvals will Health Canada likely recognize? - What are the potential eligibility criteria for devices under this new pathway? - Why is the September 12, 2026, deadline for public consultation so important? - How can manufacturers prepare their submissions to leverage this reliance route? - What documentation is needed to demonstrate equivalence with a foreign approval? - What are the immediate implications of this order for your Canadian market access strategy? - Should you re-prioritize Canada in your global launch sequence? Sources: - https://www.canada.ca/en/health-canada/news/2026/07/helping-canadians-access-safe-effective-treatments-and-medicines-faster.html How Pure Global can help: Navigating new regulatory pathways like Health Canada's Ministerial Reliance Order requires local expertise and a clear strategy. Pure Global provides end-to-end support for MedTech and IVD companies, acting as your local representative and developing efficient pathways for regulatory approval in Canada and over 30 other markets. Our experts use advanced AI to compile and manage technical dossiers, ensuring your submissions are optimized for accelerated review. Let us help you leverage your existing approvals to access the Canadian market faster. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

  4. 3日前

    UK MHRA Draft Medical Device Regulations 2026: Key Changes and Timeline

    This episode covers the closing of the WTO comment period on July 7, 2026, for the UK MHRA's draft Medical Devices (Amendment) Regulations 2026. We break down the key changes manufacturers need to prepare for, including the new international reliance pathway for approvals from other major regulators, the implementation of a UK-specific Unique Device Identification (UDI) system, and the significant shift to a risk-based classification system for In-Vitro Diagnostics (IVDs). We also discuss the expected timeline for these regulations to become law in late 2026 and provide practical steps for regulatory and quality teams to begin their transition planning. Key Questions: - What does the closing of the WTO comment period on July 7, 2026, mean for the UK's new medical device rules? - How will the proposed international reliance pathway change market access strategy for Great Britain? - What are the key details of the UK's planned Unique Device Identification (UDI) system? - How will In-Vitro Diagnostic (IVD) devices be reclassified under the new risk-based framework? - What is the expected timeline for the 2026 regulations to become law? - What steps should regulatory teams take now to prepare for these significant changes? - How do the new rules affect software as a medical device (SaMD) and implantable devices? Sources: - https://www.dacbeachcroft.com/en/gb/articles/2026/june/mhra-publishes-draft-regulations-for-medical-device-reform/ - https://www.gov.uk/government/news/mhra-invites-views-on-proposed-changes-to-medical-device-regulation - https://www.pinsentmasons.com/out-law/news/mhra-publishes-draft-2026-medical-device-regulations-for-gb-market - https://www.linkedin.com/pulse/mhra-publishes-draft-amendment-uk-medical-devices-regulations-dpcnf How Pure Global can help: Pure Global offers end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market transitions like the UK's new 2026 regulations. Our experts develop efficient regulatory strategies, leveraging new pathways like international reliance to accelerate your market access. We act as your local UK Responsible Person, manage technical dossier compilation using advanced AI, and provide continuous regulatory monitoring to ensure ongoing compliance. Whether you're a startup or a multinational, we streamline your path to the UK market. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai to get started.

  5. 4日前

    EU REP Symbol Transition: Compliance Guide for Medical Device Labeling by 2031

    This episode details the formal transition from the 'EC REP' to the 'EU REP' symbol for European Authorized Representatives on medical device and IVD labeling. We discuss the implications of the amended harmonized standard EN ISO 15223-1:2021/A1:2025, published on June 17, 2026. The host explains the 60-month transition period, which ends on June 17, 2031, and provides practical, actionable steps for manufacturers to update their technical documentation, QMS, labeling, and packaging to ensure continued compliance in the European Union. Key Questions: - What is the significance of the EU REP symbol change? - When is the official deadline to stop using the EC REP symbol? - Does this change affect both medical devices and IVDs? - What specific standard was updated to formalize this transition? - How long is the transition period for implementing the new EU REP symbol? - What are the first steps a manufacturer should take to manage this change? - How does this labeling update impact technical documentation and the QMS? - Should manufacturers coordinate this change with their Notified Body? - Can both the EC REP and EU REP symbols be used simultaneously during the transition? - What is a practical strategy for updating packaging and labeling across a large product portfolio? Sources: - https://www.medqair.com/medical-device-regulatory-news/ec-rep-to-eu-rep-what-the-ojeu-publication-means-in-practice - https://www.decomplix.com/regulatory-news/ - https://www.pure-global.com/regulatory-updates How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, develop efficient regulatory strategies, and use advanced AI to compile and manage technical dossiers for submission. Our team of local experts helps you navigate complex requirements like labeling changes to ensure your products remain compliant and reach markets faster. For support with your EU regulatory strategy and technical file updates, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and regulatory database at https://pureglobal.ai.

  6. 5日前

    Saudi Arabia SFDA Medical Device Bundling: Key Changes in Guidance MDS-G-028

    Saudi Arabia's SFDA has released a new guidance document, MDS-G-028, effective May 3, 2026, which significantly changes the rules for bundling medical devices. This episode breaks down the updated criteria for grouping devices into families, systems, and procedure packs for a single Medical Device Marketing Authorization (MDMA). We discuss the impact on submission strategies, costs, and documentation requirements, and provide practical steps for manufacturers to ensure compliance and maintain market access. Key Questions: - What is the new SFDA guidance MDS-G-028 on medical device bundling? - How does MDS-G-028 change the rules for creating a "device family" in Saudi Arabia? - What are the updated definitions for "systems" and "procedure packs"? - How will these changes affect MDMA submission costs and timelines for manufacturers? - What new documentation is required to justify a device grouping to the SFDA? - Which types of medical device companies are most affected by these new rules? - What are the implications for existing MDMAs upon renewal? - What practical steps should regulatory teams take now to prepare for this change? Sources: - https://www.complianceandrisks.com/blog/gcc-medical-devices-regulation-2026-updates-for-manufacturers/ - https://www.sfda.gov.sa/sites/default/files/2024-05/MDS-G-028.pdf - https://www.sfda.gov.sa/en/medical-devices How Pure Global can help: Pure Global provides end-to-end regulatory consulting to help MedTech and IVD companies navigate complex global markets like Saudi Arabia. Our team of local experts, supported by advanced AI, can help you develop a compliant regulatory strategy, prepare robust technical dossiers, and act as your local representative. We streamline the market access process, helping you manage submission strategies and ensure compliance with new requirements like MDS-G-028. For support with your global expansion and to access our free AI regulatory tools and database, visit us at https://pureglobal.com, contact us at info@pureglobal.com, or explore our tools at https://pureglobal.ai.

  7. 6日前

    Australia TGA UDI Requirements: High-Risk Device Compliance by July 1, 2026

    Australia's Therapeutic Goods Administration (TGA) is implementing mandatory Unique Device Identification (UDI) requirements for high-risk medical devices starting July 1, 2026. This episode details the compliance obligations for manufacturers and sponsors of Class IIb and Class III devices. We cover the core requirements for UDI assignment, labeling, and data submission to the Australian UDI Database (AusUDID), and explain how the TGA will assess compliance during pre-market review. We also provide practical steps for regulatory and quality teams to prepare for this critical market access deadline. Key Questions: - What are the new TGA UDI requirements for high-risk medical devices? - When is the compliance deadline for Class IIb and Class III devices in Australia? - How will the TGA assess UDI compliance in pre-market applications? - What information must be submitted to the Australian UDI Database (AusUDID)? - What are the first steps manufacturers should take to prepare for the July 1, 2026 deadline? - How does Australia's UDI system compare to those in the US and EU? - Which UDI issuing agencies are recognized by the TGA? - What are the future UDI deadlines for lower-risk devices? Sources: - https://www.tga.gov.au/news/news/new-udi-requirements-medical-devices-commence-1-july-2026 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, accelerating global market access. We act as your local representative and manage device registrations in over 30 countries, including Australia. Our experts develop efficient regulatory strategies and use advanced AI to compile and submit technical dossiers, minimizing delays. We help you navigate complex requirements like the TGA's UDI implementation, ensuring your products remain compliant from initial submission through post-market surveillance. Visit https://pureglobal.com or contact us at info@pureglobal.com to learn more. Explore our free AI tools and regulatory database at https://pureglobal.ai.

  8. 7月13日

    EU MDR Well-Established Technologies (WET) Exemption: New Rules for Class III and IIb Devices

    The European Commission has significantly expanded the list of 'well-established technologies' (WET) under the EU Medical Devices Regulation (MDR) as of June 29, 2026. This episode details the two new Delegated Regulations, explaining how this change exempts dozens of additional Class III and implantable devices—including certain catheters, bone fillers, and spinal fixation systems—from the default requirement to conduct clinical investigations. We explore the practical implications for manufacturers, including how to leverage this exemption to save time and resources, what kind of evidence is required for justification, and how it streamlines conformity assessment for certain Class IIb devices. Key Questions: - What are 'well-established technologies' (WET) under the EU MDR? - Which new device types were added to the WET list on June 29, 2026? - How does the WET exemption affect clinical investigation requirements for Class III devices? - What does the updated rule mean for conformity assessment of Class IIb implantable devices? - Can manufacturers of newly listed WET devices avoid conducting new clinical trials? - What kind of evidence is needed to justify using the WET exemption? - How should you update your Clinical Evaluation Report (CER) for a WET device? - What are the immediate next steps for manufacturers of devices like spinal fixation systems or dental implants? - How should you approach discussions with your Notified Body about this change? Sources: - https://www.raps.org/news-and-articles/news-articles/2026/6/european-commission-expands-list-of-well-established-technologies-under-mdr - https://www.qbd.group/en/news/new-mdr-updates-for-well-established-technologies/ - https://www.emergobyul.com/news/wet-devices-legally-expanded-european-legislation - https://www.citeline.com/insights/eu-expands-mdr-wet-exemption-list How Pure Global can help: Pure Global provides expert regulatory consulting for MedTech and IVD companies navigating complex regulations like the EU MDR. Our team can help you determine if your device qualifies under the new Well-Established Technologies (WET) exemption, develop a robust clinical evaluation strategy, and compile the necessary technical documentation to justify your approach to Notified Bodies. By combining local expertise with advanced AI, we streamline your path to market access, saving you time and resources. For end-to-end support on regulatory strategy, dossier submission, and post-market compliance, visit us at https://pureglobal.com or contact us at info@pureglobal.com. Explore our free AI tools and device database at https://pureglobal.ai.

番組について

Navigate every market. Accelerate every launch. Medical Device Global Market Access by Pure Global is the audio briefing that turns the world’s most confusing regulatory pathways into clear, actionable roadmaps. If you’re a MedTech founder, RA/QA leader, product manager, or investor who needs to get devices cleared anywhere from Austin to Abu Dhabi, this show is your shortcut. Why listen? • Step-by-step playbooks – We decode EU MDR, U.S. 510(k), Brazil’s ANVISA, China’s NMPA, and 25 + other regimes, showing exactly how long each milestone really takes and where companies get stuck. • First-hand war stories – Hear candid interviews with regulatory veterans who have shepherded implants, software, wearables, diagnostics, and AI algorithms to market—and lived to tell the tale. • Real-time intelligence – Every episode covering the week’s new guidances, standards, and enforcement trends so you’re always ahead of the curve. • Actionable templates – From clinical evaluation checklists to technical-file skeletons, we break down the documents you’ll need and the pitfalls reviewers love to flag. • AI-powered insights – Because Pure Global mines millions of public filings, tenders, and recalls, we surface data-backed best practices you won’t hear at conferences—or from competitors. What you’ll hear • Launching SaMD under multiple risk classes in parallel • Surviving an unannounced ISO 13485 audit • Building a “reg-first” QMS that scales • Mastering Latin-American registrations without endless language cycles • Leveraging real-world evidence to shorten clinical timelines • Aligning cybersecurity, privacy, and post-market surveillance rules across regions Whether you’re plotting first entry, managing lifecycle expansions, or rescuing a delayed submission, subscribing could shave months—and millions—off your path to revenue. ⸻ Brought to you by Pure Global – the AI-native consultancy that already guides MedTech innovators through regulatory and market-access hurdles in 30 + countries. Ready for expert help on your next submission? Visit https://pureglobal.com or email info@pureglobal.com to start accelerating today.